Clarity Pharmaceuticals (ASX:CU6) Marketable Securities: A$155.80 Mil (As of Dec. 2025)


ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
39 GF Score
Price A$2.41
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Marketable Securities?

Clarity Pharmaceuticals ASX:CU6 +1.69% 39 Marketable Securities is A$155.80 Mil as of Dec. 2025. GuruFocus rates ASX:CU6 with a GF Score™ of 39/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Clarity Pharmaceuticals's Marketable Securities for the quarter that ended in Dec. 2025 was A$155.80 Mil.

Clarity Pharmaceuticals's annual Marketable Securities increased from Jun. 2023 (A$33.80 Mil) to Jun. 2024 (A$88.61 Mil) but then declined from Jun. 2024 (A$88.61 Mil) to Jun. 2025 (A$36.43 Mil).

Clarity Pharmaceuticals  (ASX:CU6) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Clarity Pharmaceuticals Marketable Securities Related Terms

Clarity Pharmaceuticals Marketable Securities Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Marketable Securities Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Marketable Securities
37.00 33.80 88.61 36.43

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.81 88.61 108.22 36.43 155.80
ASX:CU6
39GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of A$155.80 Mil mean?
Clarity Pharmaceuticals (ASX:CU6) has a Marketable Securities of A$155.80 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Clarity Pharmaceuticals and its competitors.
Is Clarity Pharmaceuticals' Marketable Securities too high?
Clarity Pharmaceuticals' current Marketable Securities is A$155.80 Mil. Overall, Clarity Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Marketable Securities compare to VRTX and REGN?
Clarity Pharmaceuticals' Marketable Securities of A$155.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Clarity Pharmaceuticals and its competitors. Clarity Pharmaceuticals's current Marketable Securities is A$155.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Marketable Securities of A$155.80 Mil. The current Marketable Securities is A$155.80 Mil. Clarity Pharmaceuticals' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Marketable Securities is A$155.80 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
39GF Score

Get the complete analysis for ASX:CU6

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.41
Price